Randomization Within Biomarker Strata

Why Randomize Within Biomarker Strata?

When treatment effects or prognosis may differ across biomarker-defined groups, randomization within those groups helps ensure that each treatment arm includes patients from each group in comparable numbers. This is an allocation strategy: it controls how eligible, enrolled participants are assigned after their biomarker status is known. It does not, by itself, ensure that enough participants with a rare biomarker status will enroll.

The key design choice is whether to use separate randomization lists within prespecified strata or an adaptive allocation procedure such as minimization. Either approach should preserve genuine random assignment, keep the allocation rule concealed, and make clear which population an eventual treatment comparison represents. The discussion below assumes one baseline biomarker that has been measured and classified before randomization, with mutually exclusive strata and both treatments available in every stratum.

The strata and allocation factors should be specified before enrollment. Biomarker classification needs to be available before assignment, and the recorded status should not be changed in response to treatment or outcomes. Investigators also need an allocation system that prevents the next assignment from being predicted. A biomarker-by-site design, for example, may create many small cells; adding factors is useful only if the resulting strata can support the planned allocation.

Permuted Blocks Within Strata

For a 1:1 allocation, a permuted block of size four contains two assignments to each treatment in a randomly chosen order. Separate lists are maintained for each biomarker stratum, so the balance is pursued within each group rather than only across the trial as a whole. More generally, block sizes should be compatible with the planned allocation ratio.

With complete blocks, counts are equal at each block boundary. This is a local count-balance property, not a guarantee that each treatment group will have identical characteristics or outcomes. If enrollment stops partway through a block, the stratum may finish imbalanced. Variable block sizes, randomly selected from a prespecified set, can make the next assignment harder to guess while retaining the balancing benefit.

Minimization When Many Cells Would Be Sparse

If stratifying on several characteristics would create many small cells, minimization can balance marginal counts across selected factors without requiring a separate block sequence for every combination. At each assignment, the algorithm calculates an imbalance score for each possible treatment. The score might sum absolute differences in treatment counts across biomarker categories and sites. The participant is more likely, but not certain, to receive the treatment with the lower score.

A random component is important: deterministic assignment to the treatment with the better score can make the next assignment predictable. The exact score, factors, and randomization probabilities must be specified in advance. Minimization can balance chosen margins, but it does not guarantee balance for every combination of factors or for characteristics not included in its rule.

A practical rule for choosing between approaches is to use stratified permuted blocks when the number of important, mutually exclusive strata is manageable and accrual within each stratum is expected to be adequate. Minimization is attractive when several prognostic factors matter but their cross-classification would create numerous sparse cells. Simple randomization is simpler and remains random, but can yield more chance imbalance in small trials. None of these methods can compensate for a biomarker group that barely enrolls.

Checking Balance Without Overinterpreting It

After randomization, review counts by treatment within each biomarker stratum, and examine important baseline characteristics. For a continuous characteristic, a standardized difference can be calculated as the difference in arm means divided by a pooled standard deviation. For a binary characteristic, use the difference in proportions, with a stated scaling convention if standardizing it. These are descriptive diagnostics: they show the size of observed imbalance, not whether the allocation mechanism was valid.

Large differences may prompt a check for data errors, incorrect stratum labels, or an implementation problem. Small differences are expected by chance, especially in small strata. Baseline significance tests are not a substitute for this review: a nonsignificant result does not demonstrate balance, and a significant result does not by itself establish a randomization failure. Balance diagnostics should be considered alongside the allocation records and the prespecified procedure.

Relating Stratum Comparisons to the Trial Population

When reporting treatment results, show the treatment comparison within each biomarker stratum. If a single overall contrast is also useful, state the weights that define it. For an enrolled-population contrast, a natural choice is to weight each stratum’s treatment difference by that stratum’s share of enrolled participants. Different weights answer a different population question; they should not be chosen after seeing which result is most favorable.

For a continuous outcome, let \(\bar{x}_{As}\) and \(\bar{x}_{Bs}\) be the observed mean outcomes for treatments A and B in stratum \(s\), and let \(w_s\) be the prespecified or observed target weight for that stratum, with \(\sum_s w_s=1\). The weighted contrast is:

This expression follows by writing the weighted mean outcome in each treatment as the sum of its stratum-specific means with the same stratum weights, then subtracting:

The identity is arithmetic; interpretation depends on the weights. If treatment effects differ across biomarker groups, changing the weights changes the overall contrast. Report the stratum-specific results as well, particularly when a stratum is small or its estimate is imprecise.

Small Strata: What Randomization Can and Cannot Do

In a rare biomarker group, even a well-designed procedure may leave few participants per treatment. Small strata make count balance more sensitive to a single assignment, limit the precision of within-stratum comparisons, and can leave incomplete blocks. If a stratum has no participants on one treatment, its within-stratum treatment contrast cannot be estimated from the trial data. Randomization cannot create information that was not accrued.

Avoid adding so many stratification factors that most cells are empty or nearly empty. Conversely, do not merge biomarker categories after observing outcomes simply to improve apparent balance. Any grouping used in the allocation or analysis needs clinical justification and advance specification. If preserving random assignment within a rare biomarker group is essential, the recruitment and sample-size plan must address that need; changing the assignment algorithm alone does not solve inadequate enrollment.

In short, stratified blocks offer transparent within-stratum count balance when the strata are few and accrue adequately. Minimization can address multiple factors without creating a separate sequence for every combination, but its balance depends on the prespecified score and it remains a randomized procedure only if its allocation rule includes genuine random variation. For either method, document the rule, protect concealment, inspect the realized allocation by stratum, and match the reported treatment contrast to clearly stated population weights.